티움바이오
Financials
Valuation Metrics
티움바이오's Market Cap is ₩1343B. At end of 2025 it was ₩1799B. Ranked #1048 of 2,436 in KR market (top 43%), #531 of 1,649 on KOSDAQ (top 32%), #125 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 134.27B KRW | KR#1,048/2,436 Sec#125/234 |
| Revenue | 13.13B KRW | KR#2,245/2,436 Sec#168/234 |
| Net Income | -16.16B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 95.15B KRW | KR#1,778/2,436 Sec#144/234 |
| Net Assets | 33.72B KRW | KR#2,122/2,436 Sec#187/234 |
| Employees | 64 | KR#1,915/2,436 Sec#167/234 |
| Value | ||
| P/B | 3.98x | KR#2,200/2,436 Sec#180/234 |
| P/S | 10.22x | KR#2,273/2,436 Sec#163/234 |
| FCF Yield | -11.59% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -47.91% | KR#2,263/2,436 Sec#198/234 |
| ROA | -16.98% | KR#2,202/2,436 Sec#171/234 |
| Op. Margin | -116.80% | KR#2,321/2,436 Sec#177/234 |
| Revenue Growth | 40.07% | KR#367/2,436 Sec#34/234 |
| Financial Health | ||
| Debt Ratio | 282.14% | KR#2,095/2,436 Sec#217/234 |
| Total Debt | 29.28B KRW | KR#1,204/2,436 Sec#97/234 |
| FCF | -15.57B KRW | KR#1,837/2,436 Sec#169/234 |
| Cash | 3.38B KRW | KR#2,122/2,436 Sec#197/234 |
| Current Ratio | 1.01x | KR#1,813/2,436 Sec#182/234 |
| Performance | ||
| 1Y Return | -1.87% | KR#757/2,436 Sec#57/234 |
| 1M Return | 7.58% | KR#347/2,436 Sec#25/234 |
| From 52W High | -67.37% | KR#2,050/2,436 Sec#180/234 |
| 1Y MDD | -71.99% | KR#2,026/2,436 Sec#178/234 |
| Trading | ||
| Volume | 144,295 shares | KR#740/2,436 Sec#70/234 |
| Foreign Own. | 4.69% | KR#833/2,436 Sec#79/234 |
| Per Share | ||
| EPS | -492 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,169 KRW | KR#2,248/2,436 Sec#201/234 |
Company Info
TiumBio, established in 2016 and headquartered in Seongnam-si, Gyeonggi-do, is a research and development company focused on rare/intractable disease treatments, specially listed on KOSDAQ in 2019. In 2024, it expanded its business by a small merger with natural cosmetics company Petraon, creating the Petraon Care Lab division, while its Protium Science unit offers biopharmaceutical process development services. The company develops immunocancer drugs and endometriosis treatments through its new drug creation system, generating revenue from technology transfer and product sales.